Credit: Amgen. The Repatha Pushtronix System will be discontinued as of June 30, 2024. Amgen has announced that the Repatha (evolocumab) Pushtronix ® System (single-dose on-body infusor with prefilled ...
Amgen (AMGN) announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha. This follows landmark results demonstrating Repatha significantly reduced the risk of major ...
THOUSAND OAKS, Calif., Amgen today announced the submission of an application to the U.S. Food and Drug Administration (FDA) seeking approval of a single-dosing option for the monthly administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback